bosentan anhydrous has been researched along with Cardiovascular Diseases in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aubert, JD; Juillerat-Jeanneret, L | 1 |
| Bouras, G; Cleman, MW; Deftereos, S; Giannopoulos, G; Kaoukis, A; Panagopoulou, V; Papoutsidakis, N; Raisakis, K; Stefanadis, C | 1 |
| Goto, K; Miyauchi, T | 1 |
| McLaughlin, VV; Rich, S | 1 |
| Abassi, Z; Hoffman, A; Ramadan, R; Schwartz, H | 1 |
| Goto, K | 1 |
| Bai, N; Chang, TK; Elmi, S; Laher, I; Lemos, VS; Moien-Afshari, F; Rahman, MM; Sallam, NA | 1 |
| Ding, Y; Judd, RL; Zhong, J; Zou, R | 1 |
| Böhm, F; Pernow, J | 1 |
| Keil, U | 1 |
| Alving, K; Oldner, A; Rudehill, A; Sollevi, A; Wanecek, M; Weitzberg, E | 1 |
| Bornkessel, B | 1 |
| Bahcelioglu, M; Belloni, AS; Bova, S; Mazzocchi, G; Nussdorfer, GG; Pessina, AC; Porteri, E; Rizzoni, D; Rossi, GP; Sacchetto, A | 1 |
| Matsumori, A; Ono, K | 1 |
9 review(s) available for bosentan anhydrous and Cardiovascular Diseases
| Article | Year |
|---|---|
Endothelin-Receptor Antagonists beyond Pulmonary Arterial Hypertension: Cancer and Fibrosis.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrosis; Humans; Hypertension, Pulmonary; Neoplasms; Receptors, Endothelin | 2016 |
The role of endothelin system in cardiovascular disease and the potential therapeutic perspectives of its inhibition.
Topics: Animals; Atherosclerosis; Atrial Fibrillation; Bosentan; Cardiovascular Diseases; Coronary Artery Disease; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Humans; Hypertension, Pulmonary; Phenylpropionates; Predictive Value of Tests; Pyridazines; Receptors, Endothelin; Sulfonamides | 2013 |
[New expansion of endothelin research: perspectives for clinical application of endothelin-receptor antagonists].
Topics: Animals; Bosentan; Cardiovascular Diseases; Chronic Disease; Clinical Trials as Topic; Disease Models, Animal; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Growth Substances; Humans; Mitogens; Receptors, Endothelin; Sulfonamides; Vasoconstriction | 2003 |
Endothelin receptor blockers in cardiovascular disease.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; Exercise Tolerance; Hemodynamics; Humans; Isoxazoles; Sulfonamides; Thiophenes | 2003 |
[Therapeutic implications of endothelin antagonists for cardiovascular diseases].
Topics: Antihypertensive Agents; Bosentan; Cardiovascular Diseases; Cerebrovascular Disorders; Endothelin Receptor Antagonists; Endothelins; Humans; Sulfonamides | 2004 |
[Prospects for endothelin-related drugs].
Topics: Animals; Aspartic Acid Endopeptidases; Bosentan; Cardiovascular Diseases; Drug Design; Endothelin Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Hemodynamics; Humans; Metalloendopeptidases; Organophosphonates; Peptides, Cyclic; Quinazolines; Receptors, Endothelin; Sulfonamides; Sulfonylurea Compounds; Tetracyclines; Tetrazoles | 2004 |
The importance of endothelin-1 for vascular dysfunction in cardiovascular disease.
Topics: Animals; Bosentan; Cardiovascular Diseases; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Humans; Nitric Oxide; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Vasoconstriction | 2007 |
[Endothelial receptor antagonists].
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; Humans; Peptides, Cyclic; Receptors, Endothelin; Sulfonamides | 1997 |
Endothelin antagonism with bosentan: current status and future perspectives.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; Endothelins; Humans; Sulfonamides | 2002 |
5 other study(ies) available for bosentan anhydrous and Cardiovascular Diseases
| Article | Year |
|---|---|
Increased vascular contractility in isolated vessels from cigarette smoking rats is mediated by basal endothelin release.
Topics: Animals; Aorta, Thoracic; Bosentan; Cardiovascular Diseases; Carotid Arteries; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochromes; Dose-Response Relationship, Drug; Endothelin Receptor Antagonists; Endothelin-1; Enzyme Induction; Liver; Male; Models, Animal; Nicotiana; Nitric Oxide; Random Allocation; Rats; Rats, Sprague-Dawley; Smoke; Smoking; Sulfonamides; Time Factors; Vasoconstriction; Weight Gain | 2007 |
Endothelin-1 receptor blockade prevented the electrophysiological dysfunction in cardiac myocytes of streptozotocin-induced diabetic rats.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Body Weight; Bosentan; Calcium Channels, L-Type; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Endothelin A Receptor Antagonists; Male; Membrane Potentials; Myocardial Contraction; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels; Rats; Receptor, Endothelin A; Sulfonamides | 2006 |
[Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center].
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Bosentan; Calcium Channel Blockers; Cardiovascular Diseases; Cilazapril; Endothelins; Hemodynamics; Humans; Mibefradil; Sulfonamides; Tetrahydronaphthalenes | 1996 |
Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan.
Topics: Acid-Base Imbalance; Animals; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; Endothelin-1; Female; Hemoglobins; Hypertension, Pulmonary; Lactic Acid; Male; Oxygen Consumption; Shock, Septic; Sulfonamides; Swine; Treatment Outcome; Tumor Necrosis Factor-alpha | 1997 |
Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.
Topics: Adrenal Cortex Hormones; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypertensive Agents; Aorta; Arteries; Biphenyl Compounds; Bosentan; Cardiovascular Diseases; Dansyl Compounds; Endothelin Receptor Antagonists; Endothelium, Vascular; Hypertension; Irbesartan; Male; Mice; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Receptors, Endothelin; Renin; Sulfonamides; Tetrazoles | 2000 |